Abstract
On average, adults who smoke cigarettes weigh less than nonsmokers. However, they have a greater tendency towards abdominal obesity, and, when they stop smoking, about 80% of them gain weight. Whereas original estimates of the amount of weight ex-smokers gain in one-years time was about five pounds, long-term follow-up of sustained quitters suggests that the weight gain may be considerably greater. While the health benefits of quitting smoking outweigh the adverse health consequences of post-cessation weight gain, studies on the effects of smoking cessation on lung function show that the weight gained by quitters may significantly reduce the beneficial effects of smoking cessation on lung function. Prevention of post-cessation weight gain has proved to be an elusive target. However, studies show that life style changes, diet, exercise, and pharamacotherapy, alone and in combination, may reduce post-cessation weight gain, at least for the period of time that the treatments are in effect. Nicotine replacement therapy, bupropion SR, and, to a lesser extent, varenicline, are the most effective pharmacological deterrents to post-cessation weight gain, although the latter medication may yield the best quit smoking results. Research on pharmacogenetics and other medications may increase physicians armamentarium in the future.
Current Respiratory Medicine Reviews
Title: Smoking and Weight
Volume: 4 Issue: 2
Author(s): Norman Hymowitz
Affiliation:
Abstract: On average, adults who smoke cigarettes weigh less than nonsmokers. However, they have a greater tendency towards abdominal obesity, and, when they stop smoking, about 80% of them gain weight. Whereas original estimates of the amount of weight ex-smokers gain in one-years time was about five pounds, long-term follow-up of sustained quitters suggests that the weight gain may be considerably greater. While the health benefits of quitting smoking outweigh the adverse health consequences of post-cessation weight gain, studies on the effects of smoking cessation on lung function show that the weight gained by quitters may significantly reduce the beneficial effects of smoking cessation on lung function. Prevention of post-cessation weight gain has proved to be an elusive target. However, studies show that life style changes, diet, exercise, and pharamacotherapy, alone and in combination, may reduce post-cessation weight gain, at least for the period of time that the treatments are in effect. Nicotine replacement therapy, bupropion SR, and, to a lesser extent, varenicline, are the most effective pharmacological deterrents to post-cessation weight gain, although the latter medication may yield the best quit smoking results. Research on pharmacogenetics and other medications may increase physicians armamentarium in the future.
Export Options
About this article
Cite this article as:
Hymowitz Norman, Smoking and Weight, Current Respiratory Medicine Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339808784222830
DOI https://dx.doi.org/10.2174/157339808784222830 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Beneficial Effects of N-acetylcysteine and N-mercaptopropionylglycine on Ischemia Reperfusion Injury in the Heart
Current Medicinal Chemistry Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Atherosclerosis - New Targets and Therapeutics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Omega-3 Fatty Acids and the Expression of Membrane Proteins: Emphasis on Molecules of Immunologic Importance.
Current Organic Chemistry Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews When Does Food Refusal Require Professional Intervention?
Current Nutrition & Food Science Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutritional Deficiency in Early Life Facilitates Aging-Associated Cognitive Decline
Current Alzheimer Research Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Immunosuppression in Sepsis
Current Pharmaceutical Design A Review on the Development in the Field of NIDDM based Thiazolidinedione PPARγ Agonists
Mini-Reviews in Medicinal Chemistry Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Current Use of Cardiac Biomarkers in Various Heart Conditions
Endocrine, Metabolic & Immune Disorders - Drug Targets Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design HMG-Co A Reductase Inhibitors in the Treatment of Cardiovascular Diseases: Stabilization of Coronary Artery Plaque
Current Drug Targets Dendrimers as an Effective Nanocarrier in Cardiovascular Disease
Current Pharmaceutical Design